Pancreatic cancer cells hijack basic cell mechanism to evade immunotherapy

(NYU Langone Health / NYU School of Medicine) Pancreatic cancer cells use a normal waste removal process to hide tags on their surfaces that would otherwise let the immune system destroy them, a new study finds. Published online April 22 in Nature, the study results help to answer a longstanding question: why are pancreatic cancers so resistant to immunotherapies, which use the body's own immune defenses to fight cancer?
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

n-Wai Mai Pancreatic cancer ranks high among the causes of cancer-related mortality. The prognosis of this grim condition has not improved significantly over the past 50 years, despite advancement in imaging techniques, cancer genetics and treatment modalities. Due to the relative difficulty in the early detection of pancreatic tumors, as low as 20% of patients are eligible for potentially curative surgery; moreover, chemotherapy and radiotherapy (RT) do not confer a great benefit in the overall survival of the patients. Currently, emerging developments in immunotherapy have yet to bring a significant clinical advantag...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Patients with mesothelioma are being recruited by the National Cancer Institute for a phase II clinical trial using a novel immunotoxin prior to pembrolizumab, a combination that has shown preliminary evidence of efficacy. This promising mesothelioma clinical trial involves the drug LMB-100, designed to make immunotherapy agents such as pembrolizumab, otherwise known as Keytruda, more effective. NCI’s trial includes separate cohorts for pleural and peritoneal types of mesothelioma. “This is a very good option for these patients,” medical oncologist Dr. Raffit Hassan, an acclaimed investigator at the Natio...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion: This study reveals the existence of dysfunctional T lymphocytes with specific spatial distribution, thus opening a new dimension both conceptually and mechanistically in tumor-stroma interaction in PDAC with potential impact on the efficacy of immune-regulatory therapeutic modalities.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Authors: Moffat GT, O'Reilly EM Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that remains a challenge to treat. In pursuit of personalized medicine, researchers continue active exploration of the genetic and molecular framework of PDAC to apply novel therapeutics and enhance outcomes. In patients who have PDAC, germline mutations-such as those in the BRCA1/2 and PALB2 genes-are predominantly associated with the DNA damage response and repair pathway. On the basis of studies completed in patients with BRCA-mutated advanced breast and ovarian cancer, the poly(ADP-ribose) polymerase (PA...
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
We describe the safety profile and efficacy of IRE with nivolumab.
Source: Surgery - Category: Surgery Authors: Source Type: research
This study aimed to explore the role and regulative mechanism of CXCL5 in PDAC carcinogenesis.Materials and Methods: The expression of CXCL5 in PDAC was analyzed based on online databases and tissue microarray staining, and Western blotting of CXCL5 in PDAC cell lines and patient samples. The correlation between CXCL5 expression and clinicopathological features, prognosis and immune cell infiltration in tumor tissues was analyzed.Results: High expression of CXCL5 was observed both in PDAC tumor tissue and PDAC cell lines, compared to normal pancreas tissues and normal ductal epithelium cells. High CXCL5 expression in tumor...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Pancreatic cancer remains one of the leading causes of cancer-related death worldwide and has a poor prognosis. Current treatment relies on surgical resection and adjuvant therapies. The gut microbiota plays important roles in metabolism and immunomodulation. Accumulating evidence has implied that the gut microbiota is involved in the metabolism of chemotherapeutic drugs and the tumor microenvironment (TME), which could affect the efficacy of both conventional chemotherapy and immunotherapy for pancreatic cancer. Herein, we comprehensively reviewed the history and highlights of the interactions among pancreatic cancer, the...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In this study, we have shown that CG-745 induces microenvironment changes promoting anti-cancer effect of anti-PD-1 antibody in syngeneic mouse models. Specifically, CG-745 induces or extends IL-2 and IFN-γ expression with or without additional stimulation, and increases proliferation of cytotoxic T cells and NK cells, while inhibiting proliferation of regulatory T cells. The analysis of immune cell distribution in the tumor microenvironment and spleen reveals that CG-745 suppresses M2 macrophage polarization and decreases the myeloid-derived suppressor cells. Recent advances in immunotherapy highlight the anti-cance...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Pancreatic cancer is refractory to most current treatment options. Immunotherapy emerges as an effective and novel therapeutic strategy for several solid tumors. However, most of the clinical trials on immunot...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Commentary Source Type: research
ris Valentini Morganti Pancreatic cancer represents a modern oncological urgency. Its management is aimed to both distal and local disease control. Resectability is the cornerstone of treatment aim. It influences the clinical presentation’s definitions as up-front resectable, borderline resectable and locally advanced (unresectable). The main treatment categories are neoadjuvant (preoperative), definitive and adjuvant (postoperative). This review will focus on i) the current indications by the available national and international guidelines; ii) the current standard indications for target volume delinea...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Immunotherapy | Pancreas | Pancreatic Cancer | Study